Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor (GHS-R1a) agonist — a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Its high selectivity for GHS-R1a distinguishes it from other GH secretagogues: ipamorelin stimulates robust GH release without significantly elevating cortisol, prolactin, or ACTH levels, making it a cleaner research tool for studying GH secretion pathways.

Research demonstrates that ipamorelin produces dose-dependent increases in plasma GH levels, with peak concentrations occurring approximately 15-30 minutes post-administration. Unlike GHRP-6, ipamorelin does not significantly activate the appetite-stimulating pathways associated with ghrelin, making it more specific for GH secretion studies. The peptide also shows minimal desensitization with repeated administration, a valuable property for chronic research protocols.

Pure Pharm Peptides' Ipamorelin is verified at 99.159% purity, providing researchers with a selective GHS-R1a agonist for precise growth hormone axis investigations.

Research Applications:

• Selective GHS-R1a receptor pharmacology studies
• GH secretion without cortisol/prolactin confounding
• Pulsatile GH release pattern investigations
• Synergistic GH secretion with GHRH analog combinations
• Chronic dosing protocols with minimal desensitization
• Comparison of GH secretagogue selectivity profiles

Key Specifications:

• Purity: 99.159% verified by third-party testing
• Dosage: 5mg per vial
• Category: Growth Hormone
• Storage: -20°C or colder (lyophilized)
• Stability: Up to 2 years when stored properly

Research Highlights:

• 99.159% purity verified by independent third-party HPLC analysis
• Highly selective GHS-R1a agonist — minimal cortisol/prolactin effects
• Minimal desensitization with repeated administration
• Synergistic with GHRH analogs for amplified GH release
• Molecular weight: 711.9 Da | CAS: 170851-70-4 | PubChem CID: 9831659